Variable oral absorption of cyclosporine: A biopharmaceutical risk factor for chronic renal allograft rejection

Transplantation

Volumn 62, Issue 5, 1996, Pages 599-606

  Kahan, Barry D ^a   Welsh, Maria ^a   Schoenberg, Linda ^a   Rutzky, Lynne P ^a   Katz, Stephen M ^a   Urabauer, Diana L ^b   Van Buren, Charles T ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Applied Logic Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; PREDNISONE;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

EID: 0029789453     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609150-00010     Document Type: Article

References (34)

1. Paul LC, Benediktsson H. chronic transplant rejection: magnitude of the problem and pathogenetic mechanisms. Transplant Rev 1993; 7: 96.
2. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
3. Cho YW, Cecka JM, Terasaki PI. HLA matching effect: better survival rates and graft quality. In: Terasaki P, Cecka JM, eds. Clinical transplants 1994. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 435.
4. Didlake RH, Dreyfus KK, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20 (suppl 3): 63.
5. Brenner BM, Milford EL. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis 1993; 21: 66.
6. Tullius SG, Hancock WW, Heeman U, Azuma H, Tilney NL. Reversibility of chronic renal allograft rejection: critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 1994; 58: 93.
7. Kahan BD, Mickey R, Flechner SM, et al. Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation 1987; 43: 65.
8. Cecka JM, Terasaki PI. The UNOS scientific renal transplantation registry. In: Terasaki P, Cecka JM, eds. Clinical transplants 1994. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 1.
9. Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988; 46: 716.
10. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetic parameters, trough concentrations and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205.
11. Meyer MM, Munar M, Udeaja J, Bennett W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993; 4: 1306.
12. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
13. Lindholm A, Napoli K, Rutzky L, Kahan BD. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area under the curve monitoring of cyclosporine in renal transplantation. Ther Drug Monit 1992; 14: 292.
14. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979; 68: 1071.
15. Kahan BD, Welsh M, Rutzky L, et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992; 53: 345.
16. Browne B, Kahan BD. Renal transplantation. In: Kahan BD, ed. Surgical clinics of North America: transplantation. Philadelphia: Saunders, 1994: 1097.
17. Beck JR, Schultz EK. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986; 110: 13.
18. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283.
19. Elandt-Johnson RC, Johnson NL. Survival models and data analysis. New York: John Wiley and Sons, 1980.
20. Agresti A. Categorical data analysis. New York: John Wiley and Sons, 1990.
21. Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period-predictive of chronic rejection in liver transplantation? Transplantation 1995; 59: 1119.
22. Holt DW, Marsden JT, Johnston A, Bewick M, Taube OH. Blood cyclosporine concentrations and renal allograft dysfunction. Br Med J 1986; 293: 1057.
23. Inoue S, Beck Y, Nagao T, Uchida H. Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants. Transplant Proc 1994; 26: 2571.
24. Best NG, Trull AK, Tan KKC, et al. Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol 1992; 34: 513.
25. Blume HH, Scheidel B, Siewert M. Application of single-dose vs. multiple-dose studies. In: Midha KK, Blume HH, eds. Biointernational: bioavailability, bioequivalence and pharmacokinetics. Stuttgart: Medphram Scientific, 1993.
26. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low fat or high fat meals. Transplantation 1995; 59: 505.
27. Barone G, Chang CT, Choc MG Jr, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. Transplantation 1996; 61: 875.
28. Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism. Clin Pharmacol Ther 1989; 45: 41.
29. Kahan BD, Reid M, Newberger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 1983; 15: 446.
30. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters [Overview]. Transplantation 1985; 40: 457.
31. Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in uremic patients: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359.
32. Lindholm AS, Henricsson S, Dahlquist R. The effect of food and bile acid administration on the relative bioavailability of cyclosporine. Br J Clin Pharmacol 1990; 28: 541.
33. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Evidence for pre-hepatic metabolism of oral cyclosporine in children. Br J Clin Pharmacol 1991; 32: 477.
34. Yee GC, Stanley DL, Pessa LJ, Della Costa T, Beltz SE. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955.